Pharmacy News Article

11 November 2009 - US-based medical device company Kensey Nash Corporation (NASDAQ: KNSY) said today it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its first extracellular matrix (ECM) product, Medeor Matrix.

The clearance allows for the use of Medeor Matrix in general surgery for the reinforcement and repair of soft tissue, including hernia repair and plastic and reconstructive surgical applications, the company said.

Medeor Matrix is a porcine-based dermal extracellular matrix designed to act as a biologic scaffold to stimulate the deposition of organised tissues specific to an injured site. These ECM products facilitate rapid revascularisation and are therefore quickly repopulated with cells from the host tissue and ultimately converted into functional living tissue.

The company said that Medeor Matrix is manufactured using its proprietary Optrix process, which disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix components.

The company had previously announced a strategic agreement with Synthes Inc, whereby Synthes will market and distribute porcine dermis-based ECM products for select reconstructive surgical applications. Kensey Nash said it is currently evaluating partnering opportunities for additional applications of the Medeor Matrix products in the urogynecology, wound care, orthopedic and other markets.

((Comments on this story may be sent to tww.feedback@m2.com))